CALIFORNIA LEGISLATURE 20192020 REGULAR SESSION Assembly Bill No. 1634Introduced by Assembly Member GloriaFebruary 22, 2019 An act to amend Section 14132.70 of the Welfare and Institutions Code, relating to Medi-Cal. LEGISLATIVE COUNSEL'S DIGESTAB 1634, as introduced, Gloria. Medi-Cal: benefits: antirejection medication.Existing law provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. Under existing law, a Medi-Cal beneficiary is eligible to receive coverage for antirejection medication for up to 2 years following an organ transplant, unless the beneficiary becomes eligible for Medicare or private health insurance during that period that would cover the medication.This bill would make technical, nonsubstantive changes to those provisions.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: NO Local Program: NO Bill TextThe people of the State of California do enact as follows:SECTION 1. Section 14132.70 of the Welfare and Institutions Code is amended to read:14132.70. (a) A Medi-Cal beneficiary shall remain eligible to receive Medi-Cal coverage for antirejection medication for up to two years following after an organ transplant, unless during that period the beneficiary becomes eligible for Medicare or private health insurance during that period that would cover the medication.(b) Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section by means of all-county letters, provider bulletins, or similar instructions, without taking any further regulatory action.
CALIFORNIA LEGISLATURE 20192020 REGULAR SESSION Assembly Bill No. 1634Introduced by Assembly Member GloriaFebruary 22, 2019 An act to amend Section 14132.70 of the Welfare and Institutions Code, relating to Medi-Cal. LEGISLATIVE COUNSEL'S DIGESTAB 1634, as introduced, Gloria. Medi-Cal: benefits: antirejection medication.Existing law provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. Under existing law, a Medi-Cal beneficiary is eligible to receive coverage for antirejection medication for up to 2 years following an organ transplant, unless the beneficiary becomes eligible for Medicare or private health insurance during that period that would cover the medication.This bill would make technical, nonsubstantive changes to those provisions.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: NO Local Program: NO
CALIFORNIA LEGISLATURE 20192020 REGULAR SESSION
Assembly Bill No. 1634
Introduced by Assembly Member GloriaFebruary 22, 2019
Introduced by Assembly Member Gloria
February 22, 2019
An act to amend Section 14132.70 of the Welfare and Institutions Code, relating to Medi-Cal.
LEGISLATIVE COUNSEL'S DIGEST
## LEGISLATIVE COUNSEL'S DIGEST
AB 1634, as introduced, Gloria. Medi-Cal: benefits: antirejection medication.
Existing law provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. Under existing law, a Medi-Cal beneficiary is eligible to receive coverage for antirejection medication for up to 2 years following an organ transplant, unless the beneficiary becomes eligible for Medicare or private health insurance during that period that would cover the medication.This bill would make technical, nonsubstantive changes to those provisions.
Existing law provides for the Medi-Cal program, which is administered by the State Department of Health Care Services, under which qualified low-income individuals receive health care services. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. Under existing law, a Medi-Cal beneficiary is eligible to receive coverage for antirejection medication for up to 2 years following an organ transplant, unless the beneficiary becomes eligible for Medicare or private health insurance during that period that would cover the medication.
This bill would make technical, nonsubstantive changes to those provisions.
## Digest Key
## Bill Text
The people of the State of California do enact as follows:SECTION 1. Section 14132.70 of the Welfare and Institutions Code is amended to read:14132.70. (a) A Medi-Cal beneficiary shall remain eligible to receive Medi-Cal coverage for antirejection medication for up to two years following after an organ transplant, unless during that period the beneficiary becomes eligible for Medicare or private health insurance during that period that would cover the medication.(b) Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section by means of all-county letters, provider bulletins, or similar instructions, without taking any further regulatory action.
The people of the State of California do enact as follows:
## The people of the State of California do enact as follows:
SECTION 1. Section 14132.70 of the Welfare and Institutions Code is amended to read:14132.70. (a) A Medi-Cal beneficiary shall remain eligible to receive Medi-Cal coverage for antirejection medication for up to two years following after an organ transplant, unless during that period the beneficiary becomes eligible for Medicare or private health insurance during that period that would cover the medication.(b) Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section by means of all-county letters, provider bulletins, or similar instructions, without taking any further regulatory action.
SECTION 1. Section 14132.70 of the Welfare and Institutions Code is amended to read:
### SECTION 1.
14132.70. (a) A Medi-Cal beneficiary shall remain eligible to receive Medi-Cal coverage for antirejection medication for up to two years following after an organ transplant, unless during that period the beneficiary becomes eligible for Medicare or private health insurance during that period that would cover the medication.(b) Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section by means of all-county letters, provider bulletins, or similar instructions, without taking any further regulatory action.
14132.70. (a) A Medi-Cal beneficiary shall remain eligible to receive Medi-Cal coverage for antirejection medication for up to two years following after an organ transplant, unless during that period the beneficiary becomes eligible for Medicare or private health insurance during that period that would cover the medication.(b) Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section by means of all-county letters, provider bulletins, or similar instructions, without taking any further regulatory action.
14132.70. (a) A Medi-Cal beneficiary shall remain eligible to receive Medi-Cal coverage for antirejection medication for up to two years following after an organ transplant, unless during that period the beneficiary becomes eligible for Medicare or private health insurance during that period that would cover the medication.(b) Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section by means of all-county letters, provider bulletins, or similar instructions, without taking any further regulatory action.
14132.70. (a) A Medi-Cal beneficiary shall remain eligible to receive Medi-Cal coverage for antirejection medication for up to two years following after an organ transplant, unless during that period the beneficiary becomes eligible for Medicare or private health insurance during that period that would cover the medication.
(b) Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, interpret, or make specific this section by means of all-county letters, provider bulletins, or similar instructions, without taking any further regulatory action.